Seawolf Therapeutics, a Pathway to Cures portfolio company, has announced a multi-target collaboration with Sanofi to develop new therapies for bleeding disorders and other indications. The agreement could provide Seawolf with up to $1.2 billion in milestone payments, plus tiered royalties on future product sales.

The collaboration will leverage Seawolf's TRIDENT™ platform, a nonviral DNA delivery technology designed to overcome some of the challenges associated with traditional viral vector-based gene therapies.

Viral vectors, particularly adeno-associated virus (AAV), have been the primary method of delivering gene therapies for hemophilia. However, AAV-based approaches face several challenges, including pre-existing immunity that may make some patients ineligible for treatment and immune responses that can complicate future redosing.

Seawolf's TRIDENT technology aims to provide long-lasting production of therapeutic proteins while offering greater flexibility than traditional viral gene-delivery approaches.

The collaboration represents a significant validation of Seawolf's technology by one of the world's leading biopharmaceutical companies and highlights the potential of emerging approaches to transform treatment for bleeding disorders.

Pathway to Cures was among Seawolf's early investors, supporting the company as it advanced its nonviral gene-delivery platform and explored applications in bleeding disorders.

The collaboration marks an important milestone for Seawolf and is an encouraging example of role that early-stage investment can play in advancing innovative technologies toward potential new treatment options for patients.

“Pathway to Cures was an early investor in Seawolf Therapeutics,” said Tim Brent, managing director and officer at Pathway to Cures. “We're proud to support innovative science with the potential to create new treatment options for the bleeding disorders community.” The investment reflects Pathway to Cures' commitment to accelerating innovative research and advancing potential cures for inheritable blood and bleeding disorders.

&nsbp;